Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr:262-263:30-34.
doi: 10.1016/j.cancergen.2021.12.008. Epub 2021 Dec 24.

Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature

Robert D Johnston  1 , Farzaneh H Sayedian  1 , Christina Mendiola  2 , William Ehman Jr  2 , Veronica Ortega  2 , Gopalrao V N Velagaleti  2
Affiliations
Review

Is 5q deletion in de novo Acute Myelogenous Leukemia (AML) with excess blasts a surrogate marker for the cryptic t(7;21)(p22;q22)? A case report and review of literature

Robert D Johnston et al. Cancer Genet. 2022 Apr.

Abstract

Although the 5q- syndrome is common in both de novo and treatment related myelodysplastic syndrome (MDS) and the World Health Organization defined 5q- syndrome as a specific type of MDS, it is less common in acute myelogenous leukemia (AML). Recently, it was suggested that AML with diploidy/tetraploidy and/or 5q alterations may be associated with the cryptic translocation, t(7;21)(p22;q22) resulting in RUNX1-USP42 gene fusion and this association may have been underestimated. Here, we report another case of de novo AML with cryptic t(7;21)(p22;q22) associated with a 5q deletion.

Keywords: 5q abnormalities; Acute myeloid leukemia; Fluorescence in situ hybridization; Minimal differentiation; t(7, 21).

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Nothing to disclose.

Supplementary concepts